207 related articles for article (PubMed ID: 35883639)
1. The Impact of Infused Autograft Absolute Numbers of Immune Effector Cells on Survival Post-Autologous Stem Cell Transplantation.
Porrata LF
Cells; 2022 Jul; 11(14):. PubMed ID: 35883639
[TBL] [Abstract][Full Text] [Related]
2. Autograft mediated adoptive immunotherapy of cancer in the context of autologous stem cell transplantation.
Porrata LF; Markovic SN
World J Clin Oncol; 2010 Nov; 1(1):29-34. PubMed ID: 21603308
[TBL] [Abstract][Full Text] [Related]
3. Natural Killer Cells Are Key Host Immune Effector Cells Affecting Survival in Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation.
Porrata LF
Cells; 2022 Nov; 11(21):. PubMed ID: 36359863
[TBL] [Abstract][Full Text] [Related]
4. Autograft immune effector cells and survival in autologous peripheral blood hematopoietic stem cell transplantation.
Porrata LF
J Clin Apher; 2018 Jun; 33(3):324-330. PubMed ID: 29232011
[TBL] [Abstract][Full Text] [Related]
5. Autograft immune content and survival in non-Hodgkin's lymphoma: A post hoc analysis.
Porrata LF; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Villasboas JC; Markovic SN
Leuk Res; 2019 Jun; 81():1-9. PubMed ID: 30978434
[TBL] [Abstract][Full Text] [Related]
6. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
7. Autologous Graft-versus-Tumor Effect: Reality or Fiction?
Porrata LF
Adv Hematol; 2016; 2016():5385972. PubMed ID: 27635143
[TBL] [Abstract][Full Text] [Related]
8. Infused Autograft Absolute Lymphocyte Count Predicts Superior Survival in Diffuse Large B Cell Lymphoma Patients Post-Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation: A Matched Case-Control Study.
Porrata LF; Burgstaler EA; Winters JL; Jacob E; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Villasboas J; Paludo J; Markovic SN
Transplant Cell Ther; 2021 Sep; 27(9):769.e1-769.e8. PubMed ID: 34091071
[TBL] [Abstract][Full Text] [Related]
9. A comparison of allografting with autografting for newly diagnosed myeloma.
Bruno B; Rotta M; Patriarca F; Mordini N; Allione B; Carnevale-Schianca F; Giaccone L; Sorasio R; Omedè P; Baldi I; Bringhen S; Massaia M; Aglietta M; Levis A; Gallamini A; Fanin R; Palumbo A; Storb R; Ciccone G; Boccadoro M
N Engl J Med; 2007 Mar; 356(11):1110-20. PubMed ID: 17360989
[TBL] [Abstract][Full Text] [Related]
10. Introducing graft-versus-leukemia into autologous stem cell transplantation.
Klingemann HG
J Hematother; 1995 Aug; 4(4):261-7. PubMed ID: 7489140
[TBL] [Abstract][Full Text] [Related]
11. Infused autograft lymphocyte-to-monocyte ratio and survival in T-cell lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation.
Porrata LF; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Hogan WJ; Markovic SN
J Hematol Oncol; 2015 Jul; 8():80. PubMed ID: 26138828
[TBL] [Abstract][Full Text] [Related]
12. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications.
Steingrimsdottir H; Gruber A; Björkholm M; Svensson A; Hansson M
Haematologica; 2000 Aug; 85(8):832-8. PubMed ID: 10942930
[TBL] [Abstract][Full Text] [Related]
13. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma.
Qazilbash MH; Saliba R; De Lima M; Hosing C; Couriel D; Aleman A; Roden L; Champlin R; Giralt SA
Cancer; 2006 Mar; 106(5):1084-9. PubMed ID: 16456814
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.
Porter DL; Luger SM; Duffy KM; Stadtmauer EA; Laport G; Schuster SJ; Orloff G; Tsai D; McDaid K; Kathakali A; Leonard DG; Antin JH
Biol Blood Marrow Transplant; 2001; 7(4):230-8. PubMed ID: 11349810
[TBL] [Abstract][Full Text] [Related]
15. Severe sepsis in hematopoietic stem cell transplant recipients*.
Kumar G; Ahmad S; Taneja A; Patel J; Guddati AK; Nanchal R;
Crit Care Med; 2015 Feb; 43(2):411-21. PubMed ID: 25599465
[TBL] [Abstract][Full Text] [Related]
16. Autograft cellular composition and outcome in myeloma patients: Results of the prospective multicenter GOA study.
Turunen A; Silvennoinen R; Partanen A; Valtola J; Siitonen T; Putkonen M; Sankelo M; Pyörälä M; Kuittinen T; Penttilä K; Sikiö A; Savolainen ER; Mäntymaa P; Pelkonen J; Varmavuo V; Jantunen E
Transfusion; 2021 Jun; 61(6):1830-1844. PubMed ID: 33955591
[TBL] [Abstract][Full Text] [Related]
17. Graft Engineering and Adoptive Immunotherapy: New Approaches to Promote Immune Tolerance After Hematopoietic Stem Cell Transplantation.
Bertaina A; Roncarolo MG
Front Immunol; 2019; 10():1342. PubMed ID: 31354695
[TBL] [Abstract][Full Text] [Related]
18. Autologous and allogeneic hematopoietic stem cell transplantation in follicular lymphoma.
Bhatt VR; Armitage JO
Expert Opin Biol Ther; 2016; 16(1):57-66. PubMed ID: 26515478
[TBL] [Abstract][Full Text] [Related]
19. A Phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97.
Vesole DH; Zhang L; Flomenberg N; Greipp PR; Lazarus HM; Huff CA;
Biol Blood Marrow Transplant; 2009 Jan; 15(1):83-91. PubMed ID: 19135946
[TBL] [Abstract][Full Text] [Related]
20. Immune reconstitution after autologous hematopoietic stem cell transplantation.
Porrata LF; Litzow MR; Markovic SN
Mayo Clin Proc; 2001 Apr; 76(4):407-12. PubMed ID: 11322356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
